Omniscient Secures Third FDA Clearance, Extending Its

Omniscient secured a third FDA 510(k) clearance for its Quicktome Deep Brain (DB) workflow, extending its connectomic platform into the fast-growing deep brain stimulation market in the United States. This FDA clearance enables the company to offer personalized, patient-specific analyses that improve consistency and effectiveness of DBS therapy for movement disorders across hospitals.

This Wire brief sits within Fusion42's coverage of Medtech.